Qingran Li1, Weiping Liu1, Shidong Gao1, Yao Mao1, Yanfei Xin2. 1. Discovery Projects Unit, HitGen Inc, Building 6, No. 8 Huigu First East Road, Tianfu International Bio-Town, Shuangliu District, Chengdu, 610200, Sichuan, China. 2. Discovery Projects Unit, HitGen Inc, Building 6, No. 8 Huigu First East Road, Tianfu International Bio-Town, Shuangliu District, Chengdu, 610200, Sichuan, China. yf.xin@hitgen.com.
Abstract
BACKGROUND: Interleukin-17A (IL17A) is a proinflammatory cytokine critically involved in autoimmune diseases, and monoclonal antibodies of IL17A have been approved for clinical treatment of psoriasis. However, a usable psoriatic animal model has been always required for preclinical evaluation of IL17A antagonists. Imiquimod (IMQ)-induced psoriasis model is widely used in fundamental research, but it's not able to accurately show anti-psoriatic effect of IL17A antagonists with conventional modelling condition. RESULTS: On female C57BL/6 mice, with optimization on the usage of IMQ, positive control reagent and anti-mIL17A antibody, a 7-day model with proper testing window, acceptable disease severity as well as high repeatability was developed, and the efficacy of IL17A antagonist can be objectively evaluated by several qualitative and quantitative indices. Meanwhile, we validated the detailed involvement of IL17A signaling in disease progression, confirmed that the expression levels of IL17A and its related cytokines were induced by IMQ application, and its downstream cytokines can be inhibited by IL17A antagonist treatment. In further study, we revealed that IL17A was transient induced by IMQ and directly caused downstream signaling activation. This finding on the kinetical change of IL17A signaling will manifest the pharmacokinetics-pharmacodynamics investigation of IL17A antagonists. CONCLUSIONS: Our work presents the application of a convenient psoriatic animal model in the research and development of IL17A antagonists, meanwhile providing extra evidence for understanding IL17A's role in the progression of IMQ-induced psoriasis model, which manifest the research and development of IL17A antagonists.
BACKGROUND: Interleukin-17A (IL17A) is a proinflammatory cytokine critically involved in autoimmune diseases, and monoclonal antibodies of IL17A have been approved for clinical treatment of psoriasis. However, a usable psoriatic animal model has been always required for preclinical evaluation of IL17A antagonists. Imiquimod (IMQ)-induced psoriasis model is widely used in fundamental research, but it's not able to accurately show anti-psoriatic effect of IL17A antagonists with conventional modelling condition. RESULTS: On female C57BL/6 mice, with optimization on the usage of IMQ, positive control reagent and anti-mIL17A antibody, a 7-day model with proper testing window, acceptable disease severity as well as high repeatability was developed, and the efficacy of IL17A antagonist can be objectively evaluated by several qualitative and quantitative indices. Meanwhile, we validated the detailed involvement of IL17A signaling in disease progression, confirmed that the expression levels of IL17A and its related cytokines were induced by IMQ application, and its downstream cytokines can be inhibited by IL17A antagonist treatment. In further study, we revealed that IL17A was transient induced by IMQ and directly caused downstream signaling activation. This finding on the kinetical change of IL17A signaling will manifest the pharmacokinetics-pharmacodynamics investigation of IL17A antagonists. CONCLUSIONS: Our work presents the application of a convenient psoriatic animal model in the research and development of IL17A antagonists, meanwhile providing extra evidence for understanding IL17A's role in the progression of IMQ-induced psoriasis model, which manifest the research and development of IL17A antagonists.
Authors: Ahmed Nadeem; Sheikh F Ahmad; Naif O Al-Harbi; Ahmed M El-Sherbeeny; Mohammed M Al-Harbi; Talal S Almukhlafi Journal: Cell Signal Date: 2017-02-14 Impact factor: 4.315
Authors: Paul R Mangan; Linhui Julie Su; Victoria Jenny; Andrea L Tatum; Caryn Picarillo; Stacey Skala; Noah Ditto; Zheng Lin; XiaoXia Yang; Pete Z Cotter; David J Shuster; Yunling Song; Virna Borowski; Rochelle L Thomas; Elizabeth M Heimrich; Brigitte Devaux; Ruchira Das Gupta; Irvith Carvajal; Kim W McIntyre; Jenny Xie; Qihong Zhao; Mary Struthers; Luisa M Salter-Cid Journal: J Pharmacol Exp Ther Date: 2015-05-26 Impact factor: 4.030
Authors: William R Swindell; Kellie A Michaels; Andrew J Sutter; Doina Diaconu; Yi Fritz; Xianying Xing; Mrinal K Sarkar; Yun Liang; Alex Tsoi; Johann E Gudjonsson; Nicole L Ward Journal: Genome Med Date: 2017-03-09 Impact factor: 11.117
Authors: Rinkesh K Gupta; Donald T Gracias; Daniela Salgado Figueroa; Haruka Miki; Jacqueline Miller; Kai Fung; Ferhat Ay; Linda Burkly; Michael Croft Journal: Sci Immunol Date: 2021-11-19
Authors: Sung Shin Ahn; Hyunjin Yeo; Euitaek Jung; Yoongho Lim; Young Han Lee; Soon Young Shin Journal: Proc Natl Acad Sci U S A Date: 2022-09-06 Impact factor: 12.779
Authors: Rodrigo Boscariol; Érika A Caetano; Denise Grotto; Raquel M Rosa-Castro; José M Oliveira Junior; Marta M D C Vila; Victor M Balcão Journal: Pharmaceutics Date: 2022-04-02 Impact factor: 6.525